Dengue fever and West Nile fever are mosquito-borne diseases that affect hundreds of millions of people worldwide each year, but there is no vaccine against either of the related viruses.
A team of scientists has discovered a key aspect both to how the viruses replicate in the cells of their host and how they manipulate the immune system as they spread.
In a study available online in Science, researchers led by Janet Smith of the University of Michigan Life Sciences Institute describe for the first time the structure of a protein that helps the viruses replicate and spread infection.
“Seeing the design of this key protein provides a target for a potential vaccine or even a therapeutic drug,” Smith says.
The protein, NS1, is produced inside infected cells, where it plays a key role in replication of the virus. NS1 is also released into the bloodstream, where it may help disguise the infection from the patient’s immune system and may play a role in the hemorrhage that is seen in severe dengue virus infection.
Dengue and West Nile viruses are members of the flavivirus family, which includes yellow fever and several encephalitis viruses. Dengue, which emerged as a public health problem in the 1950s, is endemic in the majority of countries along the equatorial belt and has been reported in the southern United States, according to the Centers for Disease Control and Prevention.
West Nile virus first appeared in North America in 1999 and rapidly spread to all 48 contiguous states, with nearly 3,000 cases reported in 2013. Dengue fever affects as many as 400 million people worldwide each year.
‘It crystalized beautifully’
Smith and her colleagues created images of the protein using X-ray crystallography, a technique that uses X-ray beams to map the positions of atoms in a crystal.
“Isolating the protein in order to study it has been a challenge for researchers,” Smith says. “Once we discovered how to do that, it crystallized beautifully.”
Researchers have pursued this protein for years because both its role in replication and its unique release into the bloodstream mark it as a target for treatment of infection, says Richard Kuhn, professor and department head of biological sciences and director of the Bindley Bioscience Center at Purdue University.
“Having the structure of NS1 is a huge advance in understanding, and using, the protein to our advantage,” says Kuhn, who led the Purdue team involved in the work.
“Understanding how the protein is designed provides an easier pathway to understanding its roles in the virus life cycle. We now know which portions of the protein to target in drug development to shut it down and stop the progression of infection.”
The researchers discovered that NS1 has a 3D structure with two distinct sides, one facing the replication system of the virus inside cells it infects and the other facing the immune system outside infected cells.
“The two faces of NS1 define the regions responsible for its two major functions,” Smith says. “This understanding will guide future research into dissecting and targeting these regions in disease treatment or prevention.”
Dengue vaccine challenges
Dengue presents specific challenges for researchers working on developing a vaccine. The illness is caused by any one of four related viruses transmitted by mosquitoes. People infected by one type usually develop mild flu-like symptoms, although severe muscle and joint pain is common.
However, if subsequently bitten by a mosquito carrying another of the four types, the second exposure can lead to serious illness and death. This one-two punch greatly complicates development of a vaccine, Smith says.
“We don’t want to prime people for severe dengue disease by delivering their first exposure to the virus in the form of a vaccine,” she says.
Developing a clearer picture of how the NS1 protein interacts with the immune system and influences disease may pave the way for researchers to develop a vaccine that protects people—without inadvertently increasing their risk.
“Now that we understand the structure of the protein, we can manipulate it to probe specific functions,” Kuhn says. “This could lead to a way to prevent any harmful priming of the immune system.”
“We’re now collaborating with the Purdue virologists to understand exactly how the two faces of NS1 help the virus survive and thrive in patients,” Smith says. “These studies are the next steps toward a vaccine or an antiviral drug.”
Additional authors of the paper contributed from University of Michigan, Purdue, and Argonne National Laboratory.
The National Institutes of Health, Martha L. Ludwig Professorship of Protein Structure and Function, Pew Scholar Program in Biomedical Sciences, and Perrigo Undergraduate Summer Fellowship supported the study. The National Institute of General Medical Sciences and National Cancer Institute supported the X-ray beam lines.
Source: University of Michigan